SCHEMBL5319841

SCHEMBL5319841

CCCCN(CC)C(C)(C(=O)O)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
CA9 Q16790 2/20 0.39
ALDH1A1 P00352 3/20 0.35
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
MMP3 P08254 1/20 0.35
MMP8 P22894 1/20 0.35
KDM5A P29375 3/20 0.34
KDM4C Q9H3R0 2/20 0.34
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
AKR1B1 P15121 1/20 0.33
CA2 P00918 1/20 0.33
MAPK1 P28482 1/20 0.33
PPARG P37231 4/20 0.32
PPARD Q03181 4/20 0.32
PPARA Q07869 4/20 0.32
TSHR P16473 3/20 0.32
GPR84 Q9NQS5 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27895300 0.73 CA12 (0.38) CA12CA1CA9ALDH1A1MMP1
SCHEMBL7770548 0.72 CA12 (0.33) CA12CA1CA9ALDH1A1CA2
SCHEMBL740657 0.72 GPR84 (0.39) ALDH1A1PPARGPPARDPPARATSHR
SCHEMBL28083520 0.72 GPR84 (0.39) ALDH1A1PPARGPPARDPPARATSHR
SCHEMBL28308675 0.72 GPR84 (0.39) ALDH1A1PPARGPPARDPPARATSHR
SCHEMBL9340160 0.72 AKR1B1 (0.35) CA12CA1CA9ALDH1A1KDM5A
SCHEMBL27921659 0.71 CA12 (0.38) CA12CA1CA9ALDH1A1MMP1
SCHEMBL20521655 0.71 GRIK1 (0.36) ALDH1A1PPARGPPARDPPARATSHR
SCHEMBL6323038 0.71 GPR84 (0.38) ALDH1A1PPARGPPARDPPARATSHR
SCHEMBL28674228 0.71 GPR84 (0.38) ALDH1A1PPARGPPARDPPARATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007085933-A2 PROCESS FOR THE PREPARATION OF N-[1-(S)-ETHOXYCARBONYL-1-BUTYL]-(S)-ALANINE-DMT COMPLEX AND ITS USE IN THE PREPARATION OF PERINDOPRIL GLENMARK PHARMACEUTICALS LIMITED (US) 2007-08-02 WO disclosed
WO-2005108365-A1 PROCESSES FOR THE PREPARATION OF ALPHA POLYMORPH OF PERINDOPRIL ERBUMINE GLENMARK PHARMACEUTICALS LIMITED (US) 2005-11-17 WO disclosed
US-20050250706-A1 Processes for the preparation of alpha polymorph of perindopril erbumine GLENMARK PHARMACEUTICALS LIMITED (IN) 2005-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250706-A1 Processes for the preparation of alpha polymorph of perindopril erbumine REN, VKORC1, VKORC1L1 CA12 4558/4885CA1 4206/4885CA9 3826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.